The National Institute of Mental Health (NIMH) is now recruiting male and female patients ages 18 to 75 with chronic and/or recurrent major depression, for a trial titled Combining Medications to Enhance Depression Outcomes (CO-MED). (ClinicalTrials.gov Identifier: NCT00590863)
The Phase IV interventional trial, which will be conducted at 15 clinics in 13 states across the U.S., will test whether two different medications when given in combination as the first treatment step – compared to one medication – will:
- Improve remission rates (Currently only about one-third of patients achieve remission when treated initially with one medication.)
- Increase speed of remission,
- Be tolerable,
- And provide better sustained benefits in the longer term.
The time frame for the trial is 28 weeks, and target enrollment is more than 650 patients.
For more information about the trial and the 15 clinic locations – each with its own contact information/links – and to review the inclusion and exclusion criteria, go to the ClinicalTrials.gov description of the Combining Medications to Enhance Depression Outcomes (CO-MED) trial
For news of other trials looking for subjects in your area, track the ImmuneSupport.com Community “Current Events” listing (scroll down for latest additions).